Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme touts ‘personalized medicine’

This article was originally published in The Gray Sheet

Executive Summary

Assay for identifying patients likely to respond to non-small lung cancer drugs Tarceva (Genetech) and Iressa (AstraZeneca) are available through Genzyme's CLIA-certified laboratory in Westborough, Mass., the company announced Sept. 27. The test detects an epidermal growth factor receptor mutation - present in up to 20% of non-small-cell lung cancer patients - shown to correlate with clinical response to these treatments. Both drugs are currently prescribed only after other chemotherapy regimens have failed, but there is some interest in employing mutation testing to make them first-line treatments when appropriate...

You may also be interested in...

Diagnostics In Brief

Genzyme pharmacogenomics: Firm announces availability of its KRAS gene mutation analysis test to help identify 15%-30% of non-small cell lung cancer tumors unlikely to respond to treatment with drugs Tarceva (Genentech) or Iressa (AstraZeneca). The test, available only through Genzyme's lab, joins two other assays in the firm's portfolio that can conversely detect improved response rates to those drugs based on mutations in the epidermal growth factor receptor gene (1"The Gray Sheet" Oct. 3, 2005, In Brief). "This important convergence of diagnostics and therapeutics is a priority for the company," Genzyme says...

Merz Consumer Care Optimistic About Future As German Lockdown Continues

Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure. 

Towa Plans 10 Launches In December 2020

After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts